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ABSTRACT
The Polish Society of Gynecologists and Obstetricians and Polish Society of Colposcopy and Cervical Pathophysiology Interim 
Guidelines goal at aiding gynecologists in providing a cervical cancer prevention care during the evolving SARS-CoV-2 pan-
demic. Presented guidelines were developed on a review of limited data and updated when new relevant publications were 
revealed. Timing for deferrals of diagnostic-therapeutic procedures were mostly covered in the guidelines.  Also, a support 
for the existing Polish recommendations on abnormal screening results in a subject of minor and major screening abnor-
malities terminology were given. The guidelines are obligatory for the specified COVID-19 pandemic period only and they 
might be changed depending on the new available evidence. 
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The recommendations present current management that can be modified and changed in justified cases, after careful analysis 
of a given clinical situation, which in the future may constitute grounds for their modification and updating. 
Interim guidelines are obligatory for specified period only.
INTRODUCTION
The current national epidemiological situation rapidly 
changed due to the SARS-CoV-2 pandemic and a public 
health threat has arisen [1, 2]. The clinical management and 
diagnostic-therapeutic procedures performed so far in the 
secondary cervical cancer prevention in Poland need to 
be revisited to avoid the unnecessary virus spreading. The 
temporary guidelines for the pandemics time have been 
already introduced by some countries [3] for the patients’ 
management with abnormal screening tests results. Under-
standing the pandemic period restrictions, Polish interim 
guidelines for deferral of all non-essential medical office 
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appointments and elective procedures in the secondary 
cervical cancer screening have been developed, pursuant 
to the President of the Polish Society of Gynecologists and 
Obstetricians (PTGiP) statement of the 20th of March 2020, 
and the joint recommendations of the Polish national con-
sultants in obstetrics and gynecology together with the 
national consultants in perinatology of the 19th of March 
2020 [4, 5]. Guidelines for possible deferral of diagnostic and 
therapeutic procedures in cervical cancer prophylaxis are 
obligatory for the specified COVID-19 pandemic period only. 
RECOMMENDATIONS
The Interim guidelines are supplementary to the existing 
Polish recommendations [6–8] for the secondary cervical 
cancer prevention in the subject of a terminology for minor 
and major screening abnormalities.  
Minor screening abnormalities — a definition and the 
recommended management
Minor screening abnormalities in the pre-colposcopic 
stage encompass the following screening test results:
•	 in the primary cytology-based model the following 
results:
•	 ASC-US,
•	 LSIL,
•	 ASC-US or LSIL followed by negative HRHPV test,
•	 ASC-US or LSIL followed by negative p16/Ki67 test,
•	 ASC-US or LSIL followed by positive HRHPV type 
non-16/non-18 and negative p16/Ki67 test;
•	 in the primary cotesting-based model the following 
results:
•	 ASC-US or LSIL HRHPV-negative,
•	 ASC-US or LSIL HRHPV types non-16/non-18-positive.
Patients with minor cervical cancer screening abnormalities 
may have deferred of diagnostic tests up to 6–12 months [3].
The following management in the secondary cervical 
cancer prevention in women with abnormal minor screen-
ing tests results during the SARS-CoV-2 pandemic period is 
recommended (Tab. 1). 
Continuation of previously started screening that do 
not require leaving the place of residence is recommend-
ed, especially with the use of the liquid-based preparation 
systems. This concerns molecular testing for the high-risk 
HPV (HRHPV) and immunocytochemical p16/Ki67 testing in 
a case of ASC-US or LSIL cytology result [6–8].
HRHPV selfsampling at home is recommended if a pri-
mary molecular testing is required, or if a reflex testing is 
required in case of an ASC-US or LSIL abnormal cytology 
result [9].
Major Screening Abnormalities – a definition and the 
recommended management
Major screening abnormalities in the pre-colposcopic 
stage encompass the following screening test results:
•	 in the primary cytology-based model the following 
results:
•	 ASC-H,
•	 HSIL,
•	 ASC-US or LSIL followed by positive HRHPV type 
16 and/or 18,
•	 ASC-US or LSIL followed by positive p16/Ki67 test;
•	 in the primary cotesting-based model the following 
results:
•	 HRHPV type 16 and/or 18 positive,
•	 ASC-H, HSIL and AGC cytology results, regardless 
the HPV status;
•	 in the primary HRHPV-based selfsampling model - 
HRHPV type 16 and/or 18 positive. For HRHPV types 
non-16/non-18 positive results obtained in selfsampling 
a management algorithm depends on clinical situation 
and screening history.
Patients with major cervical cancer screening abnormali-
ties may have deferred of diagnostic tests and treatment 
maximum up to 3 months [3].
Table. 1. Recommended management during the SARS-CoV-2 pandemic in women with the minor cervical cancer screening abnormalities. 
The different screening models were given
Model of screening and detected minor screening abnormalities Recommended management*
Primary cytology
1. Deferral of diagnostic tests up to 6-12 months 
or
2. Continuation of screening that do not require leaving the 
place of residence with the use of previously sampled 
liquid-based cytologic material (if applicable)
ASC-US or LSIL
ASC-US or LSIL followed by negative HRHPV testing
ASC-US or LSIL followed by negative p16/Ki67 test
ASC-US or LSIL followed by positive HRHPV N16/N18 and negative p16/Ki67 testing
Primary co-testing
ASC-US or LSIL HRHPV-negative
ASC-US or LSIL HRHPV N16/N18-positive
ASC-US — atypical squamous cells of undetermined significance; LSIL — low-grade squamous intraepithelial lesion; HRHPV — high-risk human papillomavirus type 
*In individual cases the management might be modified depending on a clinical- and a patient-related status and/or depending on changes in a present healthcare environment
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The following management in the secondary cervical 
cancer prevention in women with abnormal major screen-
ing tests results during the SARS-CoV-2 pandemic period is 
recommended (Tab. 2). 
Histologic HSIL treatment
Specific guidelines of the gynecological societies 
adapted for the COVID-19 pandemic vary worldwide in the 
framework of histologic HSIL priority treatment [10, 11] and 
available data and evidence are limited. The conization due 
to histologic HSIL is considered by the European Society of 
Medical Oncology as a low-priority medical procedure while 
including an oncologic cervical cancer treatment of all clini-
cal stages [10]. At the end of April, the joint American state-
ment (of the eight gynecological and non-gynecological 
societies) was revealed in which authors took into account 
an epidemiological situation in a post-peak infectious curve 
when the risk of SARS-CoV-2 infection will be diminished 
and ‘a normal new’ will appear. In that document for benign 
gynecological indications on re-introduction of hospital and 
office-based procedures for the practicing gynecologists the 
CIN2 or CIN3 (HSIL) treatment was incorporated as an elec-
tive surgery of high acuity [12, 13]. Therefore, Polish interim 
guidelines suggest in the decision-making that a prioritiza-
tion of patients should be established after a careful analysis 
of a clinical status and a patient-related situation, and also 
should be modified according with the dynamically chang-
ing national healthcare environment related to COVID-19.
Invasive cervical disease
In patients with suspected invasive cervical disease 
the recommendations for a clinical management remain 
unchanged.
SUMMARY
The above Polish interim guidelines for a possible defer-
ral of diagnostic and therapeutic procedures for patients 
with abnormal screening tests results in cervical cancer 
secondary prevention in current SARS-CoV-2 pandemic 
present not the final management to proceed the patients 
with abnormal screening test results in the secondary cer-
vical cancer prevention. They do not replace a full clinical 
assessment of each individual case. The guidelines should 
always be considered in the context of the patient’s health 
interest. They may change depending on new available data.
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